Adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
to	to	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
and	and	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
mild	mild	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Report	report	O	O	O	O
of	of	O	O	O	O
Medical	medical	O	O	O	O
Research	research	O	O	O	O
Council	council	O	O	O	O
Working	working	O	O	O	O
Party	party	O	O	O	O
on	on	O	O	O	O
Mild	mild	O	O	O	O
to	to	O	O	O	O
Moderate	moderate	O	O	O	O
Hypertension	hypertension	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Participants	participants	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
Medical	medical	O	O	O	O
Research	research	O	O	O	O
Council	council	O	O	O	O
treatment	treatment	O	O	O	O
trial	trial	O	O	O	O
for	for	O	O	O	O
mild	mild	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
are	are	O	O	O	O
randomly	randomly	O	O	O	O
allocated	allocated	O	O	O	O
to	to	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
four	four	O	O	O	O
treatment	treatment	O	O	O	O
groups	groups	O	O	O	O
:	:	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
,	,	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
a	a	O	O	O	O
placebo	placebo	O	O	O	O
for	for	O	O	O	O
either	either	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
trial	trial	O	O	O	O
is	is	O	O	O	O
single-blind	single-blind	O	O	O	O
.	.	O	O	O	O

23	23	O	O	O	O
582	582	O	O	O	O
patient-years	patient-years	O	O	O	O
of	of	O	O	O	O
observation	observation	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
completed	completed	O	O	O	O
so	so	O	O	O	O
far	far	O	O	O	O
,	,	O	O	O	O
10	10	O	O	O	O
684	684	O	O	O	O
on	on	O	O	O	O
active	active	O	O	O	O
drugs	drugs	O	O	O	O
and	and	O	O	O	O
12	12	O	O	O	O
898	898	O	O	O	O
on	on	O	O	O	O
placebos	placebos	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
show	show	O	O	O	O
an	an	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
treatment	treatment	O	O	O	O
and	and	O	O	O	O
impotence	impotence	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
impotence	impotence	O	DISEASE	OTHERS	I
also	also	O	O	O	O
occurred	occurred	O	O	O	O
more	more	O	O	O	O
frequently	frequently	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
taking	taking	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
than	than	O	O	O	O
in	in	O	O	O	O
those	those	O	O	O	O
taking	taking	O	O	O	O
placebos	placebos	O	O	O	O
.	.	O	O	O	O

Other	other	O	O	O	O
adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
significantly	significantly	O	O	O	O
linked	linked	O	O	O	O
with	with	O	O	O	O
active	active	O	O	O	O
drugs	drugs	O	O	O	O
include	include	O	O	O	O
impaired	impaired	O	O	OTHERS	I
glucose	glucose	CHEMICALS	O	OTHERS	I
tolerance	tolerance	O	O	OTHERS	I
in	in	O	O	O	O
men	men	O	O	O	O
and	and	O	O	O	O
women	women	O	O	O	O
and	and	O	O	O	O
gout	gout	O	O	OTHERS	I
in	in	O	O	O	O
men	men	O	O	O	O
,	,	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
treatment	treatment	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
Raynaud	raynaud	O	O	OTHERS	I
's	's	O	O	OTHERS	I
phenomenon	phenomenon	O	O	OTHERS	I
and	and	O	O	O	O
dyspnoea	dyspnoea	O	O	OTHERS	I
in	in	O	O	O	O
men	men	O	O	O	O
and	and	O	O	O	O
women	women	O	O	O	O
taking	taking	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

No	no	O	O	O	O
corneal	corneal	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
is	is	O	O	O	O
known	known	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
.	.	O	O	O	O

Mean	mean	O	O	O	O
serum	serum	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
level	level	O	O	O	O
fell	fell	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
urea	urea	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
uric	uric	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
rose	rose	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
men	men	O	O	O	O
and	and	O	O	O	O
women	women	O	O	O	O
taking	taking	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
,	,	O	O	O	O
serum	serum	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
uric	uric	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
rose	rose	O	O	O	O
in	in	O	O	O	O
both	both	O	O	O	O
sexes	sexes	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
the	the	O	O	O	O
urea	urea	CHEMICALS	O	OTHERS	I
level	level	O	O	O	O
rose	rose	O	O	O	O
significantly	significantly	O	O	O	O
in	in	O	O	O	O
women	women	O	O	O	O
only	only	O	O	O	O
.	.	O	O	O	O

